Novel complex disease allele mutations in cleidocranial dysplasia patients

2014 ◽  
Vol 43 (10) ◽  
pp. 798-800 ◽  
Author(s):  
Robert P. Anthonappa ◽  
Fan Yan-Hui ◽  
Nigel M. King ◽  
Abu Bakr M. Rabie ◽  
Song You-Qiang
Keyword(s):  
Complex Disease ◽  
Cleidocranial Dysplasia ◽  
Disease Allele ◽  
Novel Complex

scholarly journals A novel, complex RUNX2 gene mutation causes cleidocranial dysplasia

2017 ◽  
Vol 18 (1) ◽  
Author(s):  
Wen’an Xu ◽  
Qiuyue Chen ◽  
Cuixian Liu ◽  
Jiajing Chen ◽  
Fu Xiong ◽  
...  
Keyword(s):  
Gene Mutation ◽  
Cleidocranial Dysplasia ◽  
Novel Complex

Cleidocranial dysplasia: radiological appearances on dental panoramic radiography

1999 ◽  
Vol 28 (2) ◽  
pp. 89-97 ◽  
Author(s):  
C M McNamara ◽  
B C O'Riordan ◽  
M Blake ◽  
J R Sandy
Keyword(s):  
Panoramic Radiography ◽  
Cleidocranial Dysplasia

Two novel mutations of RUNX2 gene in two sporadic cleidocranial dysplasia patients

2016 ◽  
Author(s):  
Cong Zhang ◽  
Yan Jiang ◽  
Xiaoping Xing ◽  
Mei Li ◽  
Ou Wang ◽  
...  
Keyword(s):  
Cleidocranial Dysplasia ◽  
Novel Mutations

Cleidocranial dysplasia – clinical and diagnostic considerations in two brothers

Medic ro ◽  
2019 ◽  
Vol 3 (129) ◽  
pp. 14
Author(s):  
Larisia Mihai ◽  
Cristina Mihai ◽  
Adriana Bălaşa ◽  
Adina  Ungureanu ◽  
Sergiu Chirila ◽  
...  
Keyword(s):  
Cleidocranial Dysplasia

Identification of Antineoplastic Targets with Systems Approaches, Using Resveratrol as an In-Depth Case Study

2017 ◽  
Vol 23 (32) ◽  
pp. 4773-4793 ◽  
Author(s):  
Nivedita Singh ◽  
Sherry Freiesleben ◽  
Olaf Wolkenhauer ◽  
Yogeshwer Shukla ◽  
Shailendra K. Gupta
Keyword(s):  
Drug Target ◽  
Complex Disease ◽  
Biological Targets ◽  
Systems Approaches ◽  
Anticancer Mechanism ◽  
Genetic And Environmental Factors ◽  
Key Steps ◽  
Network Approaches ◽  
Novel Drug

The identification and validation of novel drug–target combinations are key steps in the drug discovery processes. Cancer is a complex disease that involves several genetic and environmental factors. High-throughput omics technologies are now widely available, however the integration of multi-omics data to identify viable anticancer drug-target combinations, that allow for a better clinical outcome when considering the efficacy-toxicity spectrum, is challenging. This review article provides an overview of systems approaches which help to integrate a broad spectrum of technologies and data. We focus on network approaches and investigate anticancer mechanism and biological targets of resveratrol using reverse pharmacophore mapping as an in-depth case study. The results of this case study demonstrate the use of systems approaches for a better understanding of the behavior of small molecule inhibitors in receptor binding sites. The presented network analysis approach helps in formulating hypotheses and provides mechanistic insights of resveratrol in neoplastic transformations.

Sign in / Sign up

Export Citation Format

Share Document